Argos Therapeutics, Inc. is developing fully personalized immunotherapies that target unique features of a patient’s disease. This new generation of personalized therapeutics trains the immune system to recognize and attack diseases. Argos’ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform that we believe can tackle a wide range of cancers and infectious diseases.
Argos Therapeutics Reports Second Quarter 2014 Financial Results and Operational Highlights
Argos Therapeutics to Hold Second Quarter 2014 Financial Results Conference Call on Wednesday, August 13, 2014
Argos Therapeutics Presents Data Showing the Impact of HIV Antigen Sequence Divergence on Durable Viral Control Following Treatment With Autologous Immune Therapy